Jae-yong, the imprisoned de facto leader of Samsung Group, is under investigation over an allegation that he took anesthesia drug propofol shots illegally, police said on Thursday.
Propofol is a highly regulated drug in South Korea that the country's Ministry of Food and Drug Safety issued standards to prevent its misuse and abuse.
The ministry issued a notice last September to set standards for the use of narcotic drugs propofol and zolpidem, saying propofol is a "psychotropic drug used to induce and maintain the general anesthetic state."
The Gyeonggi Nambu Police Agency said they were looking into the accusation made against Lee, vice chairman of Samsung Electronics, that he illegally used the anesthesia drug at a plastic surgery clinic in Seoul last year, but refused to provide further details on the ongoing case, reports Yonhap news agency.
The police are said to have visited Lee, who is imprisoned in the Seoul Detention Center in Uiwang, south of the capital, last month to take a hair sample from him for drug testing.
Lee is currently serving a two-and-a-half-year prison term for bribing impeached former President Park Geun-hye and her longtime friend Choi Soon-sil to win government support for a smooth father-to-son transfer of managerial power at Samsung.
Samsung said that Lee only took propofol shots for medical purposes and that the police have not corroborated the allegation against him, reports Yonhap news agency.
Early last year, a similar accusation was filed against Lee with the Anti-Corruption and Civil Rights Commission that he regularly used propofol at another plastic surgery clinic in Seoul.
The case has been referred to the Supreme Prosecutors Office.
Lee also denied the allegation at that time and requested the case to be reviewed by an independent committee consisting of outside experts to see whether the prosecution's investigation is legitimate.
--IANS
wh/na
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)